Company news

Galectin Therapeutics Inc. news in 2024

Galectin Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

December 19, 2024

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

November 17, 2024

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

November 13, 2024

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

October 14, 2024

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

September 29, 2024

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

August 12, 2024

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

July 31, 2024

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

June 3, 2024

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

May 14, 2024

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

May 12, 2024

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

April 8, 2024

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

March 28, 2024

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

March 11, 2024

Decks in 2024